Influenza Prevention from CSL Biotherapies
Vaccines with Reliable Quality... Dependable Delivery
Vaccines Are Our Business, Our Passion

Vaccines are our business, our passion—and our history at CSL Biotherapies. A new name in the U.S. flu vaccine market, CSL Biotherapies is no newcomer to the global vaccine business. We’ve been making flu vaccines for 40 years. CSL Biotherapies’ flu vaccines are licensed and sold in 16 countries and we supply the antigen for vaccine in 24 countries.

CSL Biotherapies is one of the few providers of flu vaccines in the world today. That gives CSL Biotherapies a central role in helping to protect public health. It is a role we take seriously. In the face of rising global demand for flu vaccines, potentially straining international supplies, our commitment to our business and the patient is stronger than ever.

CSL is distinctive in the global vaccine market because we are extraordinarily passionate about our work—and mindful of how important our products are to the health of the patients we serve.

Company Roots

CSL Biotherapies is a company of CSL Limited, a publicly traded, global, specialty biopharmaceutical business. CSL Limited develops, manufactures and markets products to treat and prevent serious human medical conditions.

The company was founded by the Australian government in 1916 to produce vaccines and other biologicals during World War I. Over the years CSL Limited grew to produce a broad range of biotherapies. Today the company has 8,500 employees in 21 countries (more than 4,000 in the U.S.), and is a world leader in plasma therapeutics. CSL Limited’s life-saving and life-prolonging therapies are used to treat hemophilia, bleeding disorders and primary immune deficiency disorders—as well as to prevent Rh factor incompatibilities in newborns, assist recovery from heart surgery and treat shock and severe burns.

About CSL Biotherapies

Our roots in CSL Limited’s long history—and CSL Biotherapies’ 40-year track record in vaccines—are good reasons to have complete confidence in our ability to produce quality vaccines and deliver them reliably.

Our four decades in this work—driven by productive and innovative research—have allowed us to bring to market products that can mean the difference between sickness and health, between life and death. CSL Biotherapies has

---

CSL Established
The Commonwealth Serum Laboratories are established in Melbourne, Australia, to service the health needs of a nation isolated by war.

1916

Spanish Flu Pandemic
CSL produces three million doses of mixed bacterial vaccine.

1919

Poliomyelitis Vaccine Production Begins at CSL
Between 1956 and 1960, nearly 18 million doses of the Salk polio vaccine are administered.

1956

CSL Produces Split Virion Influenza Vaccine

1968

CSL Becomes Public Company
CSL is listed on Australian Stock Exchange.

1994
developed vaccines for flu; pneumonia; meningitis; diphtheria and tetanus; hepatitis; measles, mumps and rubella; rotavirus-induced gastroenteritis—and most recently, cervical cancer. Those contributions to human health come as a result of our primary dedication to the lives of our patients.

**Why CSL Biotherapies Should Supply Your Flu Vaccine**

*At CSL Biotherapies, we focus on vaccines.* CSL Biotherapies produced flu vaccine in 1968 for that year’s influenza pandemic. With 40 years’ experience, CSL Biotherapies is committed to this area of medicine—and to future growth. Our facilities provide state-of-the-art manufacturing of Afluria™, Enzira™, Fluvax™, Nilgrip™, and X-Flu™ to meet international demand. Our antigen manufacturing plant is equipped to meet demand for flu vaccines from customers in both Northern and Southern Hemisphere markets.

**CSL Biotherapies means quality.** To assure consistent quality of our vaccine, we tightly control every step of the manufacturing process and supply chain. This includes close monitoring of egg production, skillful seed development, stringent control of individual batch quality in compliance with applicable regulatory guidelines, and distribution of product that is temperature and environment controlled. This assures that every dose of vaccine reaching our patients is of consistently high quality.

**Expansion of Parkville Influenza Plant**

CSL expands operations, effectively doubling the production of influenza vaccine to supply the demands in the Northern and Southern Hemispheres.

**Thimerosal-free Influenza Vaccine Introduced**

**CSL Acquires Aventis Behring**

CSL creates ZLB Behring, now known as CSL Behring, a global leader in biotherapies.

**GARDASIL®—A Vaccine Against Cervical Cancer**

CSL’s collaboration with Merck & Co., Inc. to develop a cervical cancer vaccine succeeds. The product enters Phase III clinical trials and in 2006 receives FDA approval.

**Development of a Pandemic Flu Vaccine**

CSL continues to work toward the development, production and planned distribution of a vaccine against pandemic influenza.
CSL Biotherapies is a leading-edge innovator. In 2002, innovations in manufacture led to the approval of a thimerosal-free influenza vaccine. Our strong commitment to research and development continues to deliver important advances in health care.

Our research on adjuvants is well advanced. CSL’s ISCOMATRIX® adjuvant, which may boost the effectiveness of vaccine applications, is in clinical trials. ISCOMATRIX is well suited for vaccines that require a rapid and high antibody and cellular immune response, such as for flu prevention in the elderly. The technology has moved to a larger scale manufacturing environment at our Kankakee, Illinois, plant.

The most recent vaccine that has come to market with CSL Biotherapies’ participation is GARDASIL®. This is the world’s first vaccine against cervical cancer, the second most prevalent cancer in women. GARDASIL is the powerful result of more than 15 years of collaborative work among CSL scientists and investigators at the University of Queensland, Australia, and since 1995, the strong support of Merck, our licensee for this product. It has the potential to benefit millions of women.

CSL has responded quickly and vigorously to the international public health threat of bird flu. We have produced and are testing an experimental vaccine against the H5N1 strain.

We are working closely with public health and regulatory authorities to develop and license a safe and effective prototype vaccine as soon as possible.

Our Commitment
At CSL Biotherapies, we care about patients. We never forget that people’s lives depend upon our products. The patient is always at the center of our efforts, and we offer support services and patient-focused resources as part of this primary ongoing commitment. That commitment to the patient is embedded in the culture of the company. Our core values are:

- **Customer Focus** We are passionate about meeting the needs of our customers.
- **Innovation** We seek better ways of doing things.
- **Integrity** We are ethical and honest at all times.
- **Collaboration** We work together to achieve better results.
- **Superior Performance** We strive to be the best at what we do.

We advocate for health. That’s what CSL Biotherapies stands for. Vaccines can be a strong ally to people the world over in staying healthy. But they must be of the highest quality and delivered reliably. We are proud to be a leader in doing that—and we look forward to continuing to provide safe and effective vaccines that improve the quality of life for years to come.
Embargoed Until 9:00 am August 1
For Release: August 1, 2007

CSL Behring To Build High-Speed Syringe Fill Line
at its Kankakee (Il) Facility

--$15 million investment to fill single-dose syringes for seasonal influenza vaccine --

Kankakee, Il—August 1, 2007 -- CSL Behring today announced plans to invest $15 million to expand its manufacturing facility here by adding a high-speed, single-dose syringe filling line. Plans call for the line to be operational in 2010, when the company intends to contract with its sister company, CSL Biotherapies, to provide filling and packaging services for seasonal influenza vaccine.

CSL Biotherapies anticipates introducing its influenza vaccine to the U.S. beginning with the 2007/08 season. CSL Biotherapies has filed a Biologics License Application (BLA) with the U.S. Food and Drug Administration. The BLA requests that the vaccine be approved to immunize people 18 years of age and older. The approved vaccine will be made available in single-dose, thimerosal-free, pre-filled syringes and in multi-dose vials, providing choice and convenience to caregivers who administer it.
CSL Limited, the parent company of both CSL Behring and CSL Biotherapies, previously announced plans to invest $60 million in plant and equipment to double flu manufacturing capacity at its Melbourne, Australia facility.

“This additional $15 million investment underscores our continuing commitment to the Kankakee site,” said Randy Furby, Senior Vice President and General Manager of the facility. “CSL has made a major, long-term commitment to the U.S. vaccine market, and this building plan represents a key part of our overall business strategy.” The Kankakee facility currently employs 600 people.

About CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about saving and improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of rare diseases such as immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company
with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.

About CSL Biotherapies

The U.S. headquarters of CSL Biotherapies is located in King of Prussia, Pa. Its parent company, CSL Limited, operates one of the world’s largest influenza vaccine facilities for global markets in Melbourne, Australia. CSL Biotherapies is commercializing influenza vaccine products globally. At CSL Biotherapies, delivering vaccines is our mission, protecting lives our passion. The CSL Group, which also includes CSL Research & Development, CSL Bioplasma and CSL Behring, has more than 8,500 employees in 21 countries worldwide. For more information, visit us at www.cslbiotherapies-us.com.

Contacts:

Roger Bentley, Senior Director, Corporate Communications
CSL Behring
1020 First Avenue, King of Prussia PA 19406
610-878-4155
roger.bentley@cslbehring.com

Sheila A. Burke, Director Public Relations & Communications
Worldwide Commercial Operations, CSL Biotherapies
1020 First Avenue, King of Prussia, PA 19406-0901
610-290-7403
sheila.burke@cslbiotherapies.com